Format

Send to

Choose Destination
Chest. 2016 Dec;150(6):1371-1386. doi: 10.1016/j.chest.2016.07.027. Epub 2016 Aug 10.

Therapeutic Approach to Adult Fibrotic Lung Diseases.

Author information

1
Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, Chicago, IL. Electronic address: aadegunsoye@medicine.bsd.uchicago.edu.
2
Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, Chicago, IL.

Abstract

Among the interstitial lung diseases (ILDs), idiopathic pulmonary fibrosis (IPF), chronic hypersensitivity pneumonitis, and fibrotic connective tissue disease-related ILD are associated with a worse prognosis, with death occurring as a result of both respiratory failure and serious associated comorbidities. The recent development and approval of the antifibrotic agents nintedanib and pirfenidone, both of which reduced the rate of decline in lung function in patients with IPF in clinical trials, offer hope that it may be possible to alter the increased mortality associated with IPF. Although chronic hypersensitivity pneumonitis and connective tissue disease related-ILD may be associated with an inflammatory component, the evidence for the use of immunosuppressive agents in their treatment is largely limited to retrospective studies. The lack of benefit of immunosuppressive therapy in advanced fibrosis argues for rigorous clinical trials using antifibrotic therapies in these types of ILD as well. Patients with fibrotic ILD may benefit from identification and management of associated comorbid conditions such as pulmonary hypertension, gastroesophageal reflux, and OSA, which may improve the quality of life and, in some cases, survival in affected individuals. Because early assessment may optimize posttransplantation outcomes, lung transplant evaluation should occur early in patients with IPF and those with other forms of fibrotic ILD.

KEYWORDS:

connective tissue disease; hypersensitivity pneumonia; idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; interstitial lung disease

PMID:
27521738
PMCID:
PMC5989635
DOI:
10.1016/j.chest.2016.07.027
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center